Results 91 to 100 of about 48,194 (317)

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang, Chao Yu, Mengyue Hu, Lu Wang, Meixia Chen, Hanmo Liu, Nan Wu, Jie Hou   +7 more
wiley   +1 more source

Growth, Protein and Energy Intake in Children with PKU Taking a Weaning Protein Substitute in the First Two Years of Life: A Case-Control Study

Nutrients, 2019
Growth issues have been observed in young children with phenylketonuria (PKU), but studies are conflicting. In infancy, there is an increasing trend to introduce a second-stage semi-solid weaning protein substitute (WPS) but there is concern that this ...
S. Evans, A. Daly, J. Wildgoose, B. Cochrane, S. Chahal, C. Ashmore, Nik Loveridge, A. Macdonald   +7 more
semanticscholar   +1 more source

Supersymmetric Electroweak Corrections to Sbottom Decay into Lighter Stop and Charged Higgs Boson [PDF]

Phys.Rev.D65:035007,2002, 2001
The Yukawa corrections of order ${\cal O}(\alpha_{ew}m_{t(b)}^2/m_W^2)$, ${\cal O}(\alpha_{ew}m_{t(b)}^3/m_W^3)$ and ${\cal O}(\alpha_{ew}m_{t(b)}^4/m_W^4)$ to the width of sbottom decay into lighter stop plus charged Higgs boson are calculated in the Minimal Supersymmetric Standard Model.
arxiv   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Parenting a Child with Phenylketonuria (PKU): an Interpretative Phenomenological Analysis (IPA) of the Experience of Parents

Journal of Genetic Counseling, 2018
Phenylketonuria (PKU) is a rare inherited metabolic disorder which can cause neurological damage if left untreated. PKU is identified through newborn screening in developed countries, and treatment begins immediately to prevent these severe consequences.
Katie Carpenter, A. Wittkowski, D. Hare, E. Medford, S. Rust, Simon A. Jones, Debbie M. Smith   +6 more
semanticscholar   +1 more source

Divergent Total Syntheses of 7,20‐Epoxy, 3,20‐Epoxy, and 6,7‐seco‐ent‐Kaurane Diterpenoids

European Journal of Organic Chemistry, EarlyView.
A concise and versatile synthesis of 7,20‐epoxy‐ent‐kaurane diterpenoids is developed and its tetracyclic core is converted divergently to the skeletons of 3,20‐epoxy and 6,7‐seco‐ent‐kaurane diterpenoids via a bioinspired strategy. Collectively nine total syntheses are achieved.
Bo Wang, Wenjing Ma, Andrew‐Go Zhuang, Han Luo, Lizhi Zhu, Wei Han, Chi‐Sing Lee   +6 more
wiley   +1 more source

Molecular analysis of PKU-associated PAH mutations: a fast and simple genotyping test [PDF]

, 2018
: Neonatal screening for phenylketonuria (PKU, OMIM: 261600) was introduced at the end of the 1960s. We developed a rapid and simple molecular test for the most frequent phenylalanine hydroxylase (PAH, Gene ID: 5053) mutations.
Antonio Angeloni, ARTIOLA, CRISTIANA, CARDUCCI, Carla, CARDUCCI, Claudia, D'AMICI, SIRIO, GIOVANNIELLO, TERESA, Manuela Tolve, PASQUALI, Amelia, PIZZUTI, Antonio, Vincenzo Leuzzi   +9 more
core   +1 more source

Cognitive Outcomes in Early-Treated Adults With Phenylketonuria (PKU): A Comprehensive Picture Across Domains

Neuropsychology, 2017
Objective: Phenylketonuria (PKU) is an inherited metabolic disease which affects cognitive functions due to an inability to metabolize phenylalanine which leads to the accumulation of toxic by-products (Phe) in the brain.
L. Palermo, T. Geberhiwot, A. Macdonald, E. Limback, S. Hall, C. Romani   +5 more
semanticscholar   +1 more source

Health Related Quality of Life assessment among early-treated Hungarian adult PKU patients using the PKU-QOL adult questionnaire

Molecular Genetics and Metabolism Reports, 2020
Background: The implementation of neonatal screening and the early initiation of lifelong therapy have helped to prevent severe complications and enabled much more favorable outcomes for early-treated phenylketonuria (ETPKU) patients.
András Gellért Barta, Csaba Sumánszki, Zsófia Turgonyi, Erika Kiss, Erika Simon, Csilla Serfőző, Péter Reismann   +6 more
doaj  

The Prevalence and Incidence of Congenital Phenylketonuria in 59 Countries: A Systematic Review

Journal of Pediatrics Review, 2021
Context: Phenylketonuria (PKU) is the most frequent inborn error of metabolism, in which newborns cannot metabolize phenylalanine to tyrosine. Increased phenylalanine in untreated patients with PKU can cause serious intellectual disability; its onerous ...
Nastaran Mojibi, Shabnam Ghazanfari-Sarabi, Seyed Mohammad Bagher Hashemi-Soteh   +2 more
doaj